Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | DGKZ | Q13574 | 5/20 | 0.32 |
| ▸ | DGKA | P23743 | 4/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26926092 | 0.99 | SIGMAR1 (0.35) | SIGMAR1ACHEDGKZDGKAHRH3 | |
| SCHEMBL26925439 | 0.86 | SIGMAR1 (0.46) | SIGMAR1ACHEDGKZDGKAHRH3 | |
| Hydrochloric Acid SCHEMBL26925963 | 0.85 | SIGMAR1 (0.45) | SIGMAR1DGKZDGKAHRH3DPP8 | |
| SCHEMBL26944549 | 0.78 | SIGMAR1 (0.40) | SIGMAR1DGKZDGKAHRH3 | |
| Hydrochloric Acid SCHEMBL26925943 | 0.77 | SIGMAR1 (0.39) | SIGMAR1DGKZDGKAHRH3 | |
| SCHEMBL21831108 | 0.76 | SIGMAR1 (0.39) | SIGMAR1ACHEDGKZDGKA | |
| SCHEMBL21831106 | 0.76 | SIGMAR1 (0.39) | SIGMAR1ACHEDGKZDGKA | |
| SCHEMBL21831856 | 0.76 | SIGMAR1 (0.39) | SIGMAR1ACHEDGKZDGKA | |
| SCHEMBL30133948 | 0.76 | PDE2A (0.33) | DGKZDGKAHRH3 | |
| SCHEMBL27033982 | 0.75 | SIGMAR1 (0.43) | SIGMAR1DGKZDGKAHRH3DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | SIGMAR1 4195/4885ACHE 2172/4885DGKZ 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.